newsfilter
← Latest News
GlobeNewswire·

Wolf Popper LLP Announces Investigation on Behalf of Ionis Pharmaceuticals, Inc. Investors

  • Wolf Popper LLP is investigating potential claims for purchasers of Ionis Pharmaceuticals, Inc. (IONAS) common stock.
  • Ionis received FDA approval for its drug TRYNGOLZA in December 2024 for Familial Chylomicronemia Syndrome.
  • The FDA approved TRYNGOLZA on June 24, 2026, as an adjunct to diet for lowering triglycerides in adults with hypertriglyceridemia.
  • On November 9, 2026, Ionis reported third-quarter TRYNGOLZA sales of $9 million for the sHTG indication.
  • Management lowered full-year TRYNGOLZA sales guidance to $50 million from a previous range of $100-$110 million.
  • Ionis stock price fell $8.42 per share, or 21.4%, to $31.00 following the sales announcement.
  • Investors seeking to discuss the investigation can contact Adam Savett at (212) 451-9655 or asavett@wolfpopper.com.
  • Wolf Popper LLP is a law firm with a history of recovering billions of dollars for defrauded investors in securities litigation.
Company
Wolf Popper LLP
Keywords
Wolf Popper LLP, CLASS ACTION LAWSUIT, LAW, LEGAL, securities, Class Action